Stay up-to-date with the latest FDA approvals, trial readouts, and key clinician insights across cardiovascular care.
News|Videos|April 3, 2026
ACC 2026: Phase 2/3 Trials to Know
Author(s)Ryan Livingston
Fact checked by: Patrick Campbell
Catch up on the most impactful trial readouts to come out of ACC 2026.
Advertisement
Advertisement
The
Related to this article
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Jesus Almendral, MD, and Kanika Mody, MD, join the HCPLive team to discuss increases in hypertensive heart disease, heart failure, and other conditions.
Get a head start on one of the biggest heart failure conferences of the year with our HFSA 2026 preview.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 30 days.
FDA approved mavacamten for oHCM in children weighing 30 kg or more after SCOUT-HCM showed a 48.0-mm Hg Valsalva LVOT gradient reduction vs placebo.
Higher levels of Lp(a) are also associated with deep vein thrombosis and pulmonary embolism according to this retrospective cohort study.
In a phase 3 study, telikibart achieved EASI-75 in 69.6% of adult patients with atopic dermatitis at Week 16, with rates above 94% by Week 52.
Advertisement
Advertisement